0001786406-21-000002.txt : 20210329
0001786406-21-000002.hdr.sgml : 20210329
20210329115904
ACCESSION NUMBER: 0001786406-21-000002
CONFORMED SUBMISSION TYPE: SC 13G/A
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20210329
DATE AS OF CHANGE: 20210329
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: Gain Therapeutics, Inc.
CENTRAL INDEX KEY: 0001819411
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 851726310
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: SC 13G/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 005-92410
FILM NUMBER: 21780298
BUSINESS ADDRESS:
STREET 1: 4800 HAMPDEN LANE
STREET 2: SUITE 200
CITY: BETHESDA
STATE: MD
ZIP: 20814
BUSINESS PHONE: (301) 500-1556
MAIL ADDRESS:
STREET 1: 4800 HAMPDEN LANE
STREET 2: SUITE 200
CITY: BETHESDA
STATE: MD
ZIP: 20814
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: Titcomb Shawn
CENTRAL INDEX KEY: 0001786406
FILING VALUES:
FORM TYPE: SC 13G/A
MAIL ADDRESS:
STREET 1: 900 N. FEDERAL HWY., SUITE 400
CITY: BOCA RATON
STATE: FL
ZIP: 33432
SC 13G/A
1
titcomb13g.txt
TITCOMB 13G - GAIN THERAPEUTICS, INC.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. ___)*
Gain Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
36269B105
(CUSIP Number)
March 29, 2021
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:[_] Rule 13d-1(b) [_] Rule 13d-1(c) [X] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act
(however, see the Notes).
SCHEDULE 13G
CUSIP No.
36269B105
1. Names of Reporting Persons:
Shawn Milemore Titcomb Revocable Trust
2. Check the appropriate box if a member of a Group
(see instructions)
(a)[ ](b)[ ]
3. Sec Use Only
4. Citizenship or Place of Organization: United States
Number of Shares Beneficially Owned by Each Reporting Person With:
5. Sole Voting Power: 729,737
6. Shared Voting Power: 0
7. Sole Dispositive Power: 729,737
8. Shared Dipositive Power:
9. Aggregate Amount Beneficially Owned by Each Reporting Person: 729,737
10. Check box if the aggregate amount in row (9) excludes certain shares
(See Instructions)[ ]
11. Percent of class represented by amount in row (9): 6.1%
12. Type of Reporting Person (See Instructions): IN
Item 1.
(a) Name of Issuer:
Gain Therapeutics, Inc.
(b) Address of Issuer's Principal Executive Offices:
4800 Hampden Lane, Suite 200, Bethesda, MD 20814
Item 2.
(a) Name of Person Filing:
Shawn Milemore Titcomb Revocable Trust
(b) Address of Principal Business Office or, if None, Residence:
900 N. Federal Hwy., Suite 400, Boca Raton, Florida 33432
(c) Citizenship:
United States
(d) Title and Class of Securities:
Common Stock, $0.0001 par value per share ("Common Stock")
(e) CUSIP No.:
36269B105
Item 3.
If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b)
or(c), check whether the person filing is a: None of the categories are
applicable to the undersigned.
Item 4. Ownership
(a) Amount Beneficially Owned:
729,737
(b) Percent of Class:
The information set forth in Rows 5 through 11 on the cover page for the
Reporting Person is hereby incorporated by reference into this Item 4(b)
for the Reporting Person. The percentages reported herein are calculated
on the basis of a total of 11,876,460 shares of Common Stock outstanding
as of the date hereof, based on a statement in the Company's
Form S-1, and subsequent 8-k filed with the Securities and Exchange Commission
(the "SEC") on February 19, 2021 and March 22, 2021 respectively.
(c) Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote: 729,737
(ii) Shared power to vote or to direct the vote: 0
(iii) Sole power to dispose or to direct the disposition of: 729,737
(iv) Shared power to dispose or to direct the disposition of: 0
Item 5. Ownership of Five Percent or Less of a Class.
Not Applicable.
If this statement is being filed to report the fact that as of the date hereof
the reporting person has ceased to be the beneficial owner of more than five
percent of the class of securities, check the following [ ].
Item 6. Ownership of more than Five Percent on Behalf of Another Person.
Not Applicable.
Item 7. Identification and classification of the subsidiary which acquired the
security being reported on by the parent holding company or control person.
Not Applicable.
Item 8. Identification and classification of members of the group.
Not Applicable.
Item 9. Notice of Dissolution of Group.
Not Applicable.
Item 10. Certifications.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Dated: March 29, 2021
SHAWN MILEMORE TITCOMB REVOCABLE TRUST
/s/ Shawn Titcomb
Shawn Titcomb
Trustee
The original statement shall be signed by each person on whose behalf the
statement is filed or his authorized representative. If the statement is signed
on behalf of a person by his authorized representative (other than an executive
officer or general partner of this filing person), evidence of the
representative's authority to sign on behalf of such person shall be filed
with the statement, provided, however, that a power of attorney for this
purpose which is already on file with the Commission may be incorporated by
reference. The name and any title of each person who signs the statement shall
be typed or printed beneath his signature.
Attention: Intentional misstatements or omissions of fact constitute Federal
criminal violations (See 18 U.S.C. 1001).
Page 6 of 6